All News
Links:
Links:
TNR - Steroids and PMR
In this Tuesday Night Rheumatology webinar, the panel discussed the use of corticosteroids in patients with polymyalgia rheumatica. Panelists: Drs. Lindsay Lally, Richard Conway and Max Yates. Moderated by Dr. David Liew.
Read ArticleSAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica
NEJM reported today that polymyalgia rheumatica (PMR) patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo).
Read ArticlePredictive FDG-PET in Newly Diagnosed GCA
Annals of Internal Medicine reports that the use of 18F-fluorodeoxyglucose (FDG) PET imaging at the time of a giant cell arteritis (GCA) diagnosis may help estimate the risk for aortic aneurysm formation.
Read ArticleTNR: PMR Diagnosis and Monitoring
Panelists Dr. Claire Owen, Stephen Paget, Anisha Dua and Jack Cush discuss diagnosis and monitoring in PMR during this week's Tuesday Night Rheumatology.
Read ArticleSubclinical vasculitis in polymyalgia rheumatica
Frequent use of vascular ultrasonography and positron emission tomography and computed tomography (PET/CT) increase the possibility of encountering a patient with solely symptoms of PMR (no cranial symptoms), but giant cell arteritis (GCA) confirmed with imaging. This group of PMR patients with so-called subclinical large vasculitis represents a clinical challenge.
Read ArticleOctober is PMR Month
PMR has come a long way from being an occasional referral and often test question, to now being a hot area of drug development and investigation. Led by numerous investigators and educators worldwide, there are new insights into the diagnosis, management and outcomes of PMR patients, with greater clarity on how and where it differs from giant cell arteritis.
Read ArticleLinks:
Links:
Links: